Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30895
Title: | Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience | Authors: | RAMAEKERS, Jeroen Janssens, Joyce Waumans, Lise Stessens, Linde DUPONT, Matthias MULLENS, Wilfried MARTENS, Pieter |
Issue Date: | 2020 | Publisher: | TAYLOR & FRANCIS LTD | Source: | Acta Cardiologica, 75 (2) , p. 138 -146 | Abstract: | Background: Endomyocardial biopsies (EMBs) remain the golden standard to diagnose underlying pathophysiologic process in heart failure (HF), when potential therapeutic decisions cannot be made by non-invasive techniques. However, changes in the field of non-invasive diagnostic testing might have an impact on the need for performing an EMB in certain scenarios. Methods: We performed a retrospective analysis of consecutive EMBs performed in a single, non-academic, tertiary-care centre. EMBs were performed between February 2009 and March 2018. Baseline characteristics including non-invasive imaging and hemodynamic profile were assessed. Indications of EMBs were analysed in accordance with the 2007-AHA/ACC/ESC-scientific statement on EMBs. Results: A total of 57 patients (74% male) were included. The overall diagnostic yield was 58%, with a trend towards a higher yield in left-side (64%) versus right-side EMBs (45%; p = .346). The majority of patients (88%) underwent EMBs for a class IIa-recommendation, 9% for a class-I recommendation and the remaining patients for a class IIb-indication. Of the EMBs for a class IIa indication, 82% (n = 47) was for an unexplained restrictive cardiomyopathy, in which 53% (n = 25) revealed a diagnosis (of whom n = 23 patients had amyloidosis). Subtyping of the EMBs with a pathologic diagnosis of amyloidosis revealed that 52% (n = 12) had transthyretin amyloidosis (ATTR) and 43% (n = 10) had light-chain amyloidosis (AL). Overall one major (1.7%) and one minor (1.7%) complication occurred following the EMB-procedure. Conclusions: When following the AHA/ACC/ESC-scientific statement on EMBs, the performance of EMBs had a high diagnostic yield, with acceptable complication rates. However, in patients presenting with an unexplained restricted cardiomyopathy, technetium-labelled bone scanning could offer a non-invasive approach to establishing the diagnosis of ATTR, mitigating the need for EMBs in a subset of patients. | Notes: | Martens, P (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. pieter.martens2@zol.be |
Other: | Martens, P (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. pieter.martens2@zol.be | Keywords: | Heart failure;endomyocardial biopsy;amyloidosis;cardiovascular surgery;diagnostic yield | Document URI: | http://hdl.handle.net/1942/30895 | ISSN: | 0001-5385 | e-ISSN: | 1784-973X | DOI: | 10.1080/00015385.2018.1561597 | ISI #: | WOS:000518500300006 | Rights: | 2020 Informa UK Limited. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jobbe.pdf Restricted Access | Published version | 1.36 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
1
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
4
checked on Oct 13, 2024
Page view(s)
30
checked on Jul 22, 2022
Download(s)
2
checked on Jul 22, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.